TickerTalks
Browse all tickers →
TickerTalks›$BNTX
BNBNTX

BioNTech SE

$BNTX·$23B·Biotechnology·Healthcare
$91.99+1.8%YTD-4.6%1Y-16.9%
Mentions · last 7 days
2026-07-08: 9 posts2026-07-09: 204 posts2026-07-10: 202 posts2026-07-11: 66 posts2026-07-12: 125 posts2026-07-13: 187 posts2026-07-14: 58 posts899+28%
Price updated 2h ago·X counts updated 1h ago
BNBNTX
$BNTXBioNTech SE
$91.99+1.76%899 posts+28%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $BNTX, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersWinding up for a moveAI verdict · as of 2026-07-14

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

BioNTech at 24% of range with the Covid rev-cliff behind — the mRNA-plus-oncology pipeline is the whole story, Aug 4 is the tell.

BioNTech is the Pfizer-partnered mRNA vaccine franchise now pivoting into oncology (mRNA cancer vaccines, ADCs, TCEs). Down 19% over twelve months at 24% of the 52-week range, the setup is a post-Covid revenue rebase with a growing pipeline that Aug 4 earnings has to defend.

  • The reported mechanics show the Covid-cliff clearly: Q1 revenue declined 34% YoY to $120M with -63% gross margin (fixed-cost absorption issue at lower volume) and -520% operating margin — the earnings side is deep-negative post-Covid.
  • The pipeline is the whole story: pan-tumor mRNA vaccine BNT116 in Phase 2/3 (per prior reports), plus PD-(L)1xVEGF Sq-NSCLC data that missed on frail-patient comorbidity — real oncology optionality, but with real Phase 3 failure risk visible in the read-outs.
  • The German factory-closure news is a real balance-sheet event: BioNTech held buyer talks over four German sites set to close (Handelsblatt), and Moderna publicly said it's interested in the Germany production — a real cost restructuring supporting future pipeline economics.
  • The insider tape is quiet: two new supervisory board members (Schaffert, Low-Friedrich) filed initial Form 3s in late June — no S-Sales cluster or P-Purchases, which reads as content at 24% of range.

The path if it works is the Aug 4 Q2 print landing above the -$2.41 EPS bar with pipeline milestone updates (BNT116, ADC platform), German-site restructuring detail, and Pfizer partnership economics reaffirmed — that turns coiling into a real move alongside the biotech rotation. Continued Phase 3 misses on PD-(L)1xVEGF variants or a soft cash-runway commentary is what caps this at $90.

Agrees with X sentimentAgrees with the founders-leave-to-restart-biotech-setup framing — that story is real signal about how insiders view the pipeline runway. The corpus is thin (5 posts, June 8) so the read is more historical than fresh; the July Handelsblatt German-site closure news is the fresh data point the sentiment doesn't cover.

What to watch: Aug 4 Q2 earnings: EPS above -$2.41, pipeline milestone updates on BNT116 and ADC platform, German-site restructuring detail, and Pfizer partnership economics reaffirmed turns coiling into a move alongside biotech rotation. Continued Phase 3 misses or soft cash-runway color caps at $90.

On the calendar: 2026-08-04 — Q2 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment5 posts analyzed · as of 2026-06-08

BioNTech's chatter centers on the founders leaving to start again — bulls call this 'one of the more interesting biotech setup stories of 2026.' The bear voice is real on PD-(L)1xVEGF Sq-NSCLC data — frail patient comorbidity-loaded smokers showing OS HR 0.93 (failed). Direction skews modestly long on the setup framing.

Read the AI verdict + X sentiment for $BNTX

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

mRNA biotech known for Pfizer/BioNTech COVID vaccine, now advancing a broad cancer immunotherapy pipeline.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $BNTX.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $BNTX

Direct beneficiary — mRNA biotech known for Pfizer/BioNTech COVID vaccine, now advancing a broad cancer immunotherapy pipeline; core operations sit in the path of the GLP-1 pipeline bifurcation and ADA oral formulation competition.

Top industry ETF

$IBBiShares Biotechnology ETF
+11.9%YTD
+47.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-15.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-7.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-52.1%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
3.5%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
6.9Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-6.7%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
77.6%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 5, 2026$-2.43$-2.54+4.4%
Q4 2025Mar 10, 2026$-0.38$-0.22-72.7%
Q3 2025Nov 3, 2025$-0.14$-1.12+87.5%
Q2 2025Aug 4, 2025$-1.82$-2.69+32.3%
Next earningsTue, Aug 4·consensus EPS $-2.40

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$120.0M-34.3%-63.2%-560%$-2.14$-485.7M
Q4 FY25$898.9M-24.5%63.3%-25.7%$-1.23$237.7M
Q3 FY25$1.5B+22.0%90.2%-3.1%$-0.12$811.1M
Q2 FY25$260.8M+102.6%70.7%-192%$-1.60$700.0M

Forward consensus

5-year forecast · up to 14 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$2.2B$2.1B – $2.2B-$4.66-$4.74 – -$4.5613
FY27$2.2B$1.9B – $2.6B-$4.86-$6.70 – -$3.0012
FY28$2.6B$2.2B – $3.1B-$4.42-$9.65 – -$0.7114
FY29$2.2B$1.9B – $2.6B-$4.76-$5.87 – -$3.859
FY30$2.6B$2.2B – $3.1B-$3.84-$4.74 – -$3.1013

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.9×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.24%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-1.5%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-8.6%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 251.9M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.325-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellApr 22Sierk PoettingCOO50.0K sh$5.5M
+ 5 other (5 awards) in window

See when $BNTX insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsJun 263
AI summary

Iris Katharina Low-Friedrich was appointed to BioNTech SE's supervisory board effective June 26, 2026, and reports no securities beneficially owned. Routine initial Section 16 disclosure for the German mRNA vaccine company's new board member.

3New insider — initial holdingsJun 263
AI summary

Susanne Schaffert was appointed to BioNTech SE's supervisory board effective June 26, 2026, and reports no securities beneficially owned. Same routine initial Section 16 disclosure as the companion filing; two new supervisory board members were added to BioNTech on the same date.

3/ANew insider — initial holdingsApr 133/A
AI summary

Ugur Sahin, co-founder and CEO of BioNTech SE (BNTX), filed an amended Form 3/A on March 18, 2026, correcting or supplementing his initial ownership disclosure. Sahin is a major beneficial owner and the scientific and commercial leader of the mRNA vaccine company based in Mainz, Germany. The amendment updates the record of his initial holdings.

3New insider — initial holdingsMar 253
3New insider — initial holdingsMar 253
3New insider — initial holdingsMar 253
3New insider — initial holdingsMar 253
3New insider — initial holdingsMar 253
+ 25 other (13 6-Ks · 8 3s · 2 13Gs · 1 20-F/A) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Cathie Wood's Ark Invest Sold $7.4 Million of BioNTech Stockfool.com·2d ago2 Dirt Cheap Dividend Stocks to Buy With $1,000 Right Nowfool.com·8d agoBioNTech held buyer talks over four German sites set to close, Handelsblatt reportsreuters.com·13d agoModerna interested in Germany production, sees opportunity in BioNTech closures, says CEOreuters.com·29d agoArcus, Bristol Myers Team Up to Advance Kidney Cancer Studyzacks.com·41d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$SEER$QTTB$AGEN$REGN$MRNA$AURA$SLS$ALLO
Voices on X · top 2 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport